Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | GAA | P10253 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 13/20 | 0.38 |
| ▸ | HTR2C | P28335 | 13/20 | 0.38 |
| ▸ | HTR2B | P41595 | 13/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 2/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL710138 | 0.80 | KDM4E (0.46) | MEN1KMT2AGAAMAPTKDM4E | |
| SCHEMBL1740405 | 0.74 | KDM4E (0.35) | MEN1KMT2AMAPTKDM4EALDH1A1 | |
| SCHEMBL14979273 | 0.74 | KDM4E (0.48) | MEN1KMT2AMAPTKDM4EALDH1A1 | |
| SCHEMBL710428 | 0.74 | ALDH1A1 (0.67) | MEN1KMT2AGAAMAPTKDM4E | |
| SCHEMBL3783253 | 0.74 | ALDH1A1 (0.67) | MEN1KMT2AGAAMAPTKDM4E | |
| SCHEMBL11053842 | 0.72 | MEN1 (0.60) | MEN1KMT2AGAAMAPTKDM4E | |
| SCHEMBL708661 | 0.71 | ALDH1A1 (0.62) | MEN1KMT2AGAAMAPTKDM4E | |
| SCHEMBL710523 | 0.71 | ALDH1A1 (0.62) | MEN1KMT2AGAAMAPTKDM4E | |
| SCHEMBL14979244 | 0.71 | KDM4E (0.44) | MEN1KMT2AMAPTKDM4EALDH1A1 | |
| SCHEMBL6125325 | 0.71 | ALDH1A1 (0.62) | MEN1KMT2AGAAMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124606-B2 | Substituted 7,8,9,10-tetrahydro-5H-dipyrido[1,2-a:3′,2′-e]pyrazin-6(6aH)-ones | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-28 | — | — | US | disclosed |
| US-20110158989-A1 | Poly (ADP-Ribose) Polymerase (PARP) INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110158989-A1 | Poly (ADP-Ribose) Polymerase (PARP) INHIBITORS | PARP1, PARP3, PARP2 | MEN1 3211/4885KMT2A 1299/4885GAA 719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.